AVBP shareholders are holding stock near a $12.09 52-week low after the Phase 3 FURVENT trial missed its primary endpoint, just five months after ArriVent launched a $250 million at-the-market stock offering.

NEW YORK, Oct. 6, 2026 /PRNewswire/ — A 56.7% premarket plunge hit AVBP shareholders on October 6, 2026, after ArriVent BioPharma (NASDAQ: AVBP) announced that its Phase 3 FURVENT trial of firmonertinib did not meet its primary endpoint. If you held AVBP going into that announcement, you may be able to recover your losses. Shareholders who lost money on ArriVent are encouraged to submit your loss details now. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

Once regular trading opened, AVBP fell roughly 50% and 63%, reaching a 52-week low near $12.09; one report cited an intraday low of $11.88. The failed primary endpoint was progression-free survival by blinded independent central review in first-line patients with EGFR exon 20 insertion-mutated non-small-cell lung cancer. Firmonertinib is ArriVent’s lead product candidate.

Five months earlier, on May 11, 2026, ArriVent filed a prospectus supplement for an at-the-market offering of up to $250 million in common stock. The filing described firmonertinib’s pivotal Phase 3 program as ongoing. Levi & Korsinsky has opened an investigation into potential securities law violations on behalf of AVBP investors.

If your AVBP position is underwater after today’s drop, find out whether you can recover your losses or call (212) 363-7500.

Levi & Korsinsky, LLP — Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered.

Frequently Asked Questions About the AVBP Investigation

Q: How much did AVBP stock drop?A: Shares fell approximately 50% to 63% on October 6, 2026, reaching a 52-week low near $12.09 after the Company disclosed that its Phase 3 FURVENT trial of firmonertinib did not meet its primary endpoint. Investors who purchased shares at allegedly inflated prices and suffered losses may be eligible to seek compensation.

Q: Which statements are being investigated as potentially misleading?A: The investigation concerns whether ArriVent BioPharma made materially false or misleading statements regarding the status and prospects of its Phase 3 FURVENT trial of firmonertinib. When the Company disclosed that the trial did not meet its primary endpoint, the stock price declined sharply.

Q: When did ArriVent BioPharma allegedly mislead investors?A: The investigation concerns statements made before the October 6, 2026 disclosure that allegedly caused investors to purchase securities at inflated prices.

Q: What do AVBP investors need to do right now?A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.

Q: What documents do I need to participate?A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my AVBP shares — can I still recover losses?A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought AVBP and sold at a loss may still participate in the investigation.

Q: What if my AVBP losses are small — is it still worth contacting a lawyer?A: Yes. There is no minimum loss amount required to participate in the investigation.

Q: What does it cost me to participate?A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys’ fees and expenses subject to court approval.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

View original content to download multimedia:https://www.prnewswire.com/news-releases/arrivent-biopharma-investigation-notice-levi–korsinsky-notifies-investors-of-pending-investigation-into-arrivent-biopharma-avbp-302900197.html

SOURCE Levi & Korsinsky, LLP